US-based Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, has announced an agreement with India-based Spinco Biotech to further extend its reach in Asia. This is Parse’s latest expansion in the Asia Pacific (APAC) region following an agreement last year with Research Instruments to distribute its products in Southeast Asia.

The company’s agreement with Spinco Biotech will give researchers in India full access to its single cell portfolio, including Evercode™ Whole Transcriptome, Evercode TCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Capture, CRISPR Detect, and the Parse Biosciences data analysis solution.

The agreement is a continuation of Parse’s ongoing introduction of its products in key international markets, which are also currently available in North America, Europe, Australia, South Korea, Singapore, Israel, and New Zealand.

With technology developed at The University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $50 million in capital and is now used by over 1,000 customers across the world.